CCRCC
MCID: CLR030
MIFTS: 54

Clear Cell Renal Cell Carcinoma (CCRCC)

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

MalaCards integrated aliases for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 12 53 59 15
Clear-Cell Metastatic Renal Cell Carcinoma 12 53 72
Clear Cell Carcinoma of Kidney 12 29 6
Conventional Renal Cell Carcinoma 12 72
Renal Clear Cell Carcinoma 12 55
Clear Cell Renal Cell Adenocarcinoma 59
Conventional Renal Cell Carcinoma 12
Clear Cell Kidney Carcinoma 12
Cystic-Multilocular Variant 53
Clear Cell Renal Carcinoma 59
Clear Cell Rcc 53
Ccrcc 59

Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 44 D002292
NCIt 50 C4033
SNOMED-CT 68 41607009
ICD10 via Orphanet 34 C64
UMLS via Orphanet 73 C0279702
Orphanet 59 ORPHA319276
UMLS 72 C0279702 C2931852

Summaries for Clear Cell Renal Cell Carcinoma

NIH Rare Diseases : 53 Clear cell renal cell carcinoma is a cancer of the kidney. The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope. Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass). Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer. Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to renal cell carcinoma, nonpapillary and clear cell papillary renal cell carcinoma, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is PBRM1 (Polybromo 1). The drugs Sorafenib and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and lung.

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 34.1 TUG1 PVT1 PANDAR OGG1 MALAT1 HNF1A
2 clear cell papillary renal cell carcinoma 31.7 PBRM1 HNF1A
3 intrahepatic cholangiocarcinoma 31.1 TUG1 PBRM1 CCAT2
4 pituitary adenoma 30.7 MALAT1 CCAT2
5 cholangiocarcinoma 30.7 TUG1 SPRY4-IT1 PANDAR OGG1 MALAT1 CCAT2
6 osteogenic sarcoma 30.5 TUG1 PVT1 PANDAR MALAT1 LUCAT1 CCAT2
7 bladder urothelial carcinoma 30.4 TUG1 PVT1 MALAT1
8 pancreatic cancer 30.2 TUG1 SPRY4-IT1 PVT1 MALAT1 CYTOR
9 lung squamous cell carcinoma 30.2 TUG1 PVT1 CCAT2
10 gastric cancer 30.2 TUG1 SPRY4-IT1 PVT1 PANDAR MALAT1 CYTOR
11 myeloma, multiple 30.2 TUG1 PVT1 MALAT1
12 bladder cancer 30.1 TUG1 SPRY4-IT1 PVT1 PCAT29 PANDAR MALAT1
13 lung cancer susceptibility 3 29.8 TUG1 PCAT29 OGG1 MALAT1 DRAIC DGCR5
14 breast cancer 29.7 TUG1 SPRY4-IT1 PVT1 PANDAR NBAT1 MALAT1
15 prostate cancer 29.7 TUG1 SPRY4-IT1 PVT1 PCAT29 MALAT1 DRAIC
16 lung cancer 29.7 TUG1 SPRY4-IT1 PVT1 PANDAR OGG1 MALAT1
17 hepatocellular carcinoma 29.0 TUG1 SPRY4-IT1 PVT1 PCAT29 PANDAR MALAT1
18 multilocular clear cell renal cell carcinoma 12.7
19 hereditary conventional renal cell carcinoma 12.7
20 multilocular cystic renal neoplasm of low malignant potential 11.9
21 von hippel-lindau syndrome 11.9
22 chromophobe renal cell carcinoma 11.7
23 bap1 tumor predisposition syndrome 11.7
24 kidney cancer 11.1
25 microvascular complications of diabetes 3 10.7 PVT1 MALAT1
26 renal cell carcinoma, papillary, 1 10.7
27 chromophil renal cell carcinoma 10.7
28 oncocytoma 10.6
29 angiomyolipoma 10.6
30 small cell cancer of the lung 10.5 TUG1 MALAT1 CCAT2
31 oral squamous cell carcinoma 10.5 TUG1 MALAT1 CCAT2
32 malignant glioma 10.5 TUG1 SPRY4-IT1 PVT1 CYTOR
33 gallbladder cancer 10.5 TUG1 MALAT1 CYTOR
34 hemangioblastoma 10.4
35 hypoxia 10.4
36 glioma 10.4 SPRY4-IT1 PVT1 MALAT1 LUCAT1 CYTOR CCAT2
37 severe combined immunodeficiency 10.4
38 renal cell carcinoma 4 10.4
39 squamous cell carcinoma 10.4 TUG1 SPRY4-IT1 MALAT1 CCAT2
40 renal oncocytoma 10.4
41 hypothyroidism 10.3
42 collecting duct carcinoma 10.3
43 adenoma 10.3
44 immunodeficiency, common variable, 10 10.3
45 exanthem 10.3
46 adenocarcinoma 10.3
47 cervical cancer 10.3 TUG1 SPRY4-IT1 PVT1 PANDAR MALAT1 CCAT2
48 brain glioma 10.3 PCAT29 DRAIC
49 tuberous sclerosis 10.2
50 spindle cell carcinoma 10.2

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2
Ipilimumab Approved Phase 3 477202-00-9
3
nivolumab Approved Phase 3 946414-94-4
4
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
5
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
6
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
7
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
8 Interferon-alpha Phase 3
9 interferons Phase 3
10 Interferon alpha-2 Phase 3
11 Anti-Infective Agents Phase 3
12 Antifungal Agents Phase 3
13 Anti-Bacterial Agents Phase 3
14 Antibiotics, Antitubercular Phase 3
15 Immunosuppressive Agents Phase 3
16 Mitogens Phase 3
17 Endothelial Growth Factors Phase 3
18 Immunoglobulin G Phase 3
19
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 46507594 772
20
Tinzaparin Approved Phase 1, Phase 2 9005-49-6, 9041-08-1 25244225
21
Dalteparin Approved Phase 1, Phase 2 9005-49-6
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
24
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
25
Zoledronic Acid Approved Phase 1, Phase 2 118072-93-8 68740
26
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
27
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
28
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
29
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
32
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
33
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
34
Acetaminophen Approved Phase 2 103-90-2 1983
35
Ethanol Approved Phase 2 64-17-5 702
36
Benzyl alcohol Approved Phase 2 100-51-6 244
37
Denosumab Approved Phase 2 615258-40-7
38
Selenium Approved, Investigational, Vet_approved Phase 1, Phase 2 7782-49-2
39
Clobetasol Approved, Experimental, Investigational Phase 2 25122-46-7, 25122-41-2 32798 5311051
40
Olaparib Approved Phase 2 763113-22-0 23725625
41
Adenosine Approved, Investigational Phase 2 58-61-7 60961
42
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
43
Talazoparib Approved, Investigational Phase 1, Phase 2 1207456-01-6 135565082
44
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
45
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
46
Metformin Approved Phase 1, Phase 2 657-24-9 4091 14219
47
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
48
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
49
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
50
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 231)
# Name Status NCT ID Phase Drugs
1 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
2 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
3 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
4 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
5 Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making. Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
6 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
7 A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) Completed NCT00087022 Phase 3
8 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
9 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
10 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
11 An International, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate Whether TroVax, Added to First-line Standard of Care Therapy, Prolongs the Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma. Completed NCT00397345 Phase 3
12 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma Completed NCT00326898 Phase 3 Sorafenib Tosylate;Sunitinib Malate
13 A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses Recruiting NCT03849118 Phase 3
14 PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Recruiting NCT03793166 Phase 3 Cabozantinib
15 A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Active, not recruiting NCT01668784 Phase 3 Everolimus
16 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Active, not recruiting NCT01120249 Phase 3 everolimus
17 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
18 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Terminated NCT02535351 Phase 3 sunitinib or pazopanib
19 Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC Terminated NCT01599754 Phase 3 Axitinib;Placebo
20 Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors Terminated NCT01198158 Phase 3 Everolimus
21 An Open Label, Phase IIIB, Single Arm, Multicenter Safety Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma Withdrawn NCT03693573 Phase 3 Atezolizumab;Bevacizumab
22 A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
23 A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus Unknown status NCT01798446 Phase 2 Axitinib
24 Phase II Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma Unknown status NCT01219751 Phase 2 Sunitinib
25 Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma Patients: a Prospective Study Unknown status NCT01069770 Phase 2 Sunitinib
26 Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
27 A Phase I/II Trial of Tinzaparin (Innohep), a Low Molecular Weight Heparin (LMWH) for Treatment of Advanced Renal Cell Carcinoma Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
28 A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study Unknown status NCT00301990 Phase 2
29 SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies Unknown status NCT00535379 Phase 2 Sunitinib
30 Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study Unknown status NCT01791387 Phase 2 Dovitinib
31 A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma Completed NCT00278174 Phase 2
32 Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00408902 Phase 2 tandutinib
33 G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
34 Phase II Study Of Lutetium-177 Labeled Chimeric Monoclonal Antibody Girentuximab (177Lu-DOTA-girentuximab) in Patients With Advanced Renal Cell Cancer Completed NCT02002312 Phase 2 Lu-177-DOTA-girentuximab
35 Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma Completed NCT00401128 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
36 Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma Completed NCT00853021 Phase 2
37 A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma Completed NCT00830895 Phase 2 RAD001
38 Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Completed NCT00465179 Phase 2 Sunitinib Malate
39 Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma Completed NCT00979966 Phase 2 Temsirolimus;Sunitinib
40 A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer Completed NCT01408004 Phase 2 Pazopanib;Everolimus;Pazopanib;Everolimus;Everolimus;Pazopanib
41 pazopanib_NCRCC,Ph2 STUDY Completed NCT01538238 Phase 2 pazopanib
42 A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma Completed NCT02923531 Phase 1, Phase 2 X4P-001;Nivolumab
43 An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
44 Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer Completed NCT00142415 Phase 1, Phase 2 111-In-DOTA-cG250;177-Lu-DOTA-cG250
45 Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Completed NCT01182142 Phase 2 Capecitabine
46 A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients Completed NCT00276614 Phase 2 bortezomib
47 A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2 GW786034;Placebo
48 A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma Completed NCT00193258 Phase 1, Phase 2 Bevacizumab;Erlotinib;Imatinib
49 A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy Completed NCT00866320 Phase 2 sorafenib tosylate
50 A Phase 2, Multi-Center, Randomized, Open-Label Study of Two Dose Levels of IMOxine® (IMO-2055 for Injection) in Patients With Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2 IMO-2055

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Genetic tests related to Clear Cell Renal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 29

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

41
Kidney, Endothelial, Lung, T Cells, Brain, Bone, Neutrophil

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 3432)
# Title Authors PMID Year
1
VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. 9 38
20431476 2010
2
Loss of expression of TIMP3 in clear cell renal cell carcinoma. 9 38
20194016 2010
3
The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. 9 38
19683801 2010
4
The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. 9 38
20022054 2010
5
Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. 9 38
19963243 2010
6
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 9 38
20054297 2010
7
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. 9 38
19695674 2009
8
Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. 9 38
19731255 2009
9
Microarray analysis of microRNA expression in renal clear cell carcinoma. 88
19443172 2009
10
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]. 9 38
20021866 2009
11
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. 9 38
19671223 2009
12
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. 9 38
19539328 2009
13
Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. 9 38
19219613 2009
14
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. 9 38
19402074 2009
15
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. 9 38
19296514 2009
16
[Methylation of promoter region of RASSF1A gene and frequencies of allelic imbalances in chromosome 3 critical regions are correlated with progression of clear cell renal cell carcinoma]. 9 38
19548529 2009
17
Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. 9 38
19302703 2009
18
Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. 9 38
19073886 2009
19
Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. 9 38
18660794 2009
20
Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. 9 38
19759417 2009
21
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. 9 38
18635227 2008
22
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. 9 38
18695901 2008
23
Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity. 9 38
18604734 2008
24
Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. 9 38
18669472 2008
25
Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. 9 38
18538369 2008
26
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. 9 38
18464292 2008
27
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. 9 38
18565906 2008
28
Expression of prostate-specific membrane antigen in renal cortical tumors. 9 38
18344976 2008
29
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. 9 38
18300814 2008
30
Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. 9 38
18076934 2008
31
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. 9 38
17997430 2008
32
Expression of claudin-7 in benign kidney and kidney tumors. 9 38
18784823 2008
33
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. 9 38
18094421 2007
34
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. 9 38
18043042 2007
35
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. 9 38
17947723 2007
36
Characterization of a 3;6 translocation associated with renal cell carcinoma. 9 38
17205537 2007
37
Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. 9 38
17449941 2007
38
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. 9 38
17382701 2007
39
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. 9 38
17188329 2007
40
Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. 9 38
17270362 2007
41
Activation of the mTOR signaling pathway in renal clear cell carcinoma. 9 38
17162089 2007
42
[Expression of Ksp-cadherin in renal epithelial neoplasm and its clinicopathologic significance]. 9 38
17374232 2007
43
The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. 9 38
16983094 2006
44
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. 9 38
16736510 2006
45
[Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof]. 9 38
16854277 2006
46
Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors. 9 38
16600797 2006
47
[Expression of cytokeratin 5 and calretinin in clear-cell renal cell carcinoma]. 9 38
16838608 2006
48
Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. 9 38
16107702 2005
49
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. 9 38
15893810 2005
50
Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. 9 38
15578072 2005

Variations for Clear Cell Renal Cell Carcinoma

ClinVar genetic disease variations for Clear Cell Renal Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 3:9792107-9792107 3:9750423-9750423
2 PBRM1 NM_018313.5(PBRM1): c.3923_3930del (p.Asp1308fs) deletion Pathogenic rs864321679 3:52597380-52597387 3:52563364-52563371
3 HNF1A NM_000545.6(HNF1A): c.872dup (p.Gly292fs) duplication Pathogenic rs587776825 12:121432125-121432125 12:120994322-120994322
4 HNF1A NM_000545.6(HNF1A): c.92G> A (p.Gly31Asp) single nucleotide variant Uncertain significance rs137853247 12:121416663-121416663 12:120978860-120978860

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9 (show top 50) (show all 2155)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 9
2 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 9
3 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 9
4 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 9
5 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 9
6 COSM6970086 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 9
7 COSM3276983 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 9
8 COSM6961023 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 9
9 COSM6935891 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
10 COSM6946890 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 9
11 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
12 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 16:69936391-69936391 9
13 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 11:32434810-32434810 9
14 COSM6201648 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1228+1G>C p.? 11:32391971-32391971 9
15 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 23:54238942-54238942 9
16 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13:41701456-41701456 9
17 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13:41865963-41865963 9
18 COSM6930635 VTCN1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.98-1G>T p.? 1:117156922-117156922 9
19 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 8:99274262-99274262 9
20 COSM14311 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.499C>T p.R167W 3:10149822-10149822 9
21 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 9
22 COSM14375 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.343C>T p.H115Y 3:10146516-10146516 9
23 COSM17715 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.221T>A p.V74D 3:10142068-10142068 9
24 COSM17855 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.233A>G p.N78S 3:10142080-10142080 9
25 COSM18024 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.598C>T p.R200W 3:10149921-10149921 9
26 COSM18074 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.193T>C p.S65P 3:10142040-10142040 9
27 COSM18152 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463G>A p.V155M 3:10146636-10146636 9
28 COSM30224 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.326T>G p.I109S 3:10142173-10142173 9
29 COSM14318 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.231C>A p.C77* 3:10142078-10142078 9
30 COSM14373 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.400G>T p.E134* 3:10146573-10146573 9
31 COSM14389 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.452T>G p.I151S 3:10146625-10146625 9
32 COSM97151 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.477A>T p.K159N 3:10149800-10149800 9
33 COSM1417312 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.424G>A p.V142I 3:10146597-10146597 9
34 COSM14400 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 3:10142041-10142041 9
35 COSM17657 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.472C>G p.L158V 3:10149795-10149795 9
36 COSM17909 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.482G>C p.R161P 3:10149805-10149805 9
37 COSM18350 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.256C>T p.P86S 3:10142103-10142103 9
38 COSM14290 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.240T>A p.S80R 3:10142087-10142087 9
39 COSM14407 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>C p.V130L 3:10146561-10146561 9
40 COSM18005 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.340+1G>A p.? 3:10142188-10142188 9
41 COSM18353 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.331A>G p.S111G 3:10142178-10142178 9
42 COSM18355 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.453C>G p.I151M 3:10146626-10146626 9
43 COSM14346 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.266T>C p.L89P 3:10142113-10142113 9
44 COSM14380 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.548C>A p.S183* 3:10149871-10149871 9
45 COSM18015 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>A p.S65* 3:10142041-10142041 9
46 COSM97142 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.264G>T p.W88C 3:10142111-10142111 9
47 COSM97146 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.357C>A p.F119L 3:10146530-10146530 9
48 COSM14363 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.458T>C p.L153P 3:10146631-10146631 9
49 COSM17731 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.288G>T p.Q96H 3:10142135-10142135 9
50 COSM17983 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.500G>A p.R167Q 3:10149823-10149823 9

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

GO Terms for Clear Cell Renal Cell Carcinoma

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....